

GLOBAL MARKETS FOR GENERIC DRUGS



PHM009H
February 2017

Paul Evers
Project Analyst

ISBN: 1-62296-437-3



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
info@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	3
MARKET ANALYSES AND FORECASTS	3
METHODOLOGY	3
INTENDED AUDIENCE	3
INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
MARKET SIZE AND EVOLUTION	8
<i>SUMMARY TABLE GLOBAL MARKET FOR GENERIC DRUGS, BY REGION, THROUGH 2021 (\$ BILLIONS)</i>	9
<i>SUMMARY FIGURE GLOBAL MARKET FOR GENERIC DRUGS, BY REGION, 2014-2021 (\$ BILLIONS)</i>	9
CHAPTER 3 OVERVIEW	11
<i>TABLE 1 GLOBAL PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS)</i>	12
RECENT HISTORY OF THE GENERICS SECTOR	13
ROCHE-BOLAR	13
GENERICS LOBBY	14
ICH	15
CHAPTER 4 THE NEW GENERICS ERA	17
THE PATENT CLIFF	18
<i>TABLE 2 MAJOR RECENT AND UPCOMING PATENT EXPIRIES, 2014-2020</i>	18
<i>TABLE 3 BRAND SALES BEFORE AND AFTER PATENT EXPIRY (\$ MILLIONS)</i>	19
TYPES OF GENERICS	19
SIMPLE GENERICS	20
Adequate Market Size	20
Patent-expired Therapies	20
Older Products Still Used	21
Long-term Use	21
Straightforward Production Technology	21
Drugs Used in Primary Care	22
SUPERGENERICS	22
BIOSIMILARS	23
<i>TABLE 4 BIOTHERAPEUTICS AMONG TOP 40 PRESCRIPTION PHARMACEUTICALS, 2015 (\$ BILLIONS)</i>	24
<i>TABLE 5 BIOLOGICS WITH RECENT OR UPCOMING LOSS OF PATENT PROTECTION</i>	24
SPECIAL CHALLENGES	26

TOPIC	PAGE NO.
THE BIOSIMILARS MARKET	28
Biosimilar Developments and Introductions	28
EPO	28
G-CSF	29
Interferons	29
hGH	29
Monoclonal Antibodies	29
CHAPTER 5 MAJOR GENERIC ISSUES	32
REGULATORY ENVIRONMENT	32
UNITED STATES	32
<i>TABLE 6 REQUIREMENTS FOR NDA AND ANDA APPLICATIONS</i>	33
EUROPEAN UNION	34
EU Marketing Authorization Systems	35
The Centralized Procedure	35
Decentralized and Mutual Recognition Procedures	36
Mutual Recognition Procedure	37
Types of Applications	37
Applications Under Article 10 (Generic Products)	38
JAPAN	38
Approval of Pharmaceuticals	39
REGULATION OF BIOSIMILARS	39
EU Provisions	40
Evolving Situation in the U.S.	40
User Fees	42
Hatch-Waxman and Bolar	42
DEFENSIVE STRATEGIES BY "BIG PHARMA"	43
"AUTHORIZED GENERICS"	44
User Fees	45
Changing Climate for Generics	45
Situation in Europe	46
PATENTS AND IP	47
SUPPLEMENTARY PROTECTION CERTIFICATES	48
CHAPTER 6 THE GENERICS MARKET	51
GLOBAL PHARMACEUTICAL AND GENERICS MARKET	51
GLOBAL GENERICS MARKET	51
MAIN NATIONAL GENERICS MARKETS	51
<i>TABLE 7 GLOBAL MARKET FOR PHARMA AND GENERIC DRUGS, THROUGH 2021 (\$ BILLIONS)</i>	52
<i>TABLE 8 GLOBAL MARKET FOR GENERIC DRUGS, BY COUNTRY, THROUGH 2021 (\$ BILLIONS)</i>	52
MARKET OPPORTUNITIES BY PRODUCT CLASS	52
LEADING GENERIC MOLECULES	52
<i>TABLE 9 TOP 20 GENERIC MOLECULES, BY PRESCRIPTION SALES, 2015 (\$ BILLIONS)</i>	53
<i>TABLE 10 GLOBAL TOP-SELLING PRESCRIPTION PHARMACEUTICALS</i>	54
Anti-infectives	55
<i>TABLE 11 LEADING ANTI-INFECTIVE PRODUCT SALES, 2015 (\$ MILLIONS)</i>	56

TOPIC	PAGE NO.
CNS Therapies	56
Antidepressants	57
Antipsychotics	58
<i>TABLE 12 LEADING CNS PRODUCT SALES, 2015 (\$ MILLIONS)</i>	58
Anxiolytics	59
Sleep Disorders	59
Epilepsy	60
Parkinson's Disease	61
Migraine	61
Cardiovascular Products	61
<i>TABLE 13 LEADING CARDIOVASCULAR PRODUCT SALES, 2015 (\$ MILLIONS)</i>	62
Anti-arthritis Products	63
Steroids	63
NSAIDs	63
COX-II Inhibitors	64
DMARDs	65
<i>TABLE 14 LEADING ANTI-ARTHRITIS PRODUCT SALES, 2015 (\$ MILLIONS)</i>	65
Respiratory Products	66
Asthma	66
COPD	66
Allergic Rhinitis	67
Bronchodilators	67
Inhaled bronchodilators	67
Anticholinergics	68
Oral bronchodilators	68
Leukotriene antagonists	68
Steroids	69
<i>FIGURE 1 GLOBAL MARKET SHARE OF ASTHMA PRODUCT CATEGORIES (%)</i>	69
<i>TABLE 15 LEADING RESPIRATORY PRODUCT SALES, 2015 (\$ MILLIONS)</i>	70
Anticancer Products	70
Cytotoxic Drugs	70
Hormonal Therapy	71
Biologic Response Modifiers	71
Anti-angiogenesis Drugs	71
Monoclonal Antibodies	71
<i>TABLE 16 LEADING ANTICANCER PRODUCT SALES, 2015 (\$ MILLIONS)</i>	72
CHAPTER 7 GENERICS MARKETS AND FORECASTS BY COUNTRY	75
AMERICAS	75
UNITED STATES	75
Vital Statistics	75
Health and Healthcare	75
Pharmaceutical Market	76
<i>TABLE 17 U.S. PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)</i>	77
Generics Market	77
Biosimilars	77
Generic Prices	77

TOPIC	PAGE NO.
"Carve-outs"	78
Generics Industry	78
The Future	79
CANADA	79
Vital Statistics	79
Pharmaceutical Market	80
<i>TABLE 18 CANADA'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)</i>	80
Generics Market	80
Prices of Generics	81
How Generics Are Supplied	82
BRAZIL	82
Vital Statistics	82
Pharmaceutical Market	83
<i>TABLE 19 BRAZIL'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)</i>	83
Generics Market	84
M&A Activity	86
Future Prospects	86
ProGenericos	87
ASIA	87
JAPAN	87
Vital Statistics	87
Health and Healthcare	87
Pharmaceutical Market	88
<i>TABLE 20 JAPAN'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)</i>	88
<i>TABLE 21 TOP 25 JAPANESE PHARMA COMPANIES (\$ MILLIONS/%)</i>	89
Generics Market	90
Generics Industry	92
INDIA	93
Vital Statistics	93
Health and Healthcare	93
Growing Affluence - Changing Medical Needs	93
Pharmaceutical Market	93
<i>TABLE 22 INDIA'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)</i>	94
Pharma Industry	95
Patent Reform	95
Generics Industry	96
<i>TABLE 23 LEADING PHARMA COMPANIES IN INDIA, 2012 (\$ MILLIONS)</i>	96
CHINA	97
Vital Statistics	97
Health and Healthcare	97
Pharmaceutical Market	98
<i>TABLE 24 CHINA'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)</i>	99
Domestic Industry	99

TOPIC	PAGE NO.
Foreign Company Involvement	100
Importance of R&D	102
Challenges	102
Market Trends	102
Regulatory Changes	103
Generics Exports	103
Domestic Generics Market	104
Local Dominance	104
EUROPE	105
FRANCE	106
Vital Statistics	106
Health and Healthcare	106
Healthcare Provision	106
<i>FIGURE 2 HEALTH EXPENDITURE IN MAJOR EUROPEAN MARKETS AND THE U.S., 2014 (PERCENTAGE OF GDP)</i>	106
Pharmaceutical Market	108
<i>TABLE 25 FRANCE'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)</i>	108
Generics Market	108
GERMANY	110
Vital Statistics	110
Health and Healthcare	110
Provision of Healthcare	110
Pharmaceutical Market	111
Price Controls	111
<i>TABLE 26 GERMANY'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)</i>	112
Generics Market	113
ITALY	113
Vital Statistics	113
Health and Healthcare	114
Healthcare System	114
Pharmaceutical Market	114
<i>TABLE 27 ITALY'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)</i>	116
Pharmaceutical Industry	116
Generics Market	117
SPAIN	118
Vital Statistics	118
Health and Healthcare	118
Healthcare Provision	118
Pharmaceutical Services	119
Pharmaceutical Market	119
<i>TABLE 28 SPAIN'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)</i>	120
Generics Market	120
Generics Industry	121
<i>TABLE 29 LEADING GENERICS COMPANIES IN SPAIN, 2015 (\$ MILLIONS)</i>	121

TOPIC	PAGE NO.
UNITED KINGDOM	121
Vital Statistics	122
Health and Healthcare	122
Healthcare Provision	122
Private Sector Involvement	122
Pharmaceuticals	123
Pharmaceutical Market	123
<i>TABLE 30 LEADING PHARMA COMPANIES IN THE U.K., BY MARKET SHARE, 2013 (%)</i>	124
Generics Market	124
<i>TABLE 31 U.K.'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)</i>	125
RUSSIA	126
Vital Statistics	127
Health and Healthcare	127
Healthcare Delivery	127
Pharmaceutical Market	127
Pharma 2020	128
<i>TABLE 32 RUSSIA'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)</i>	129
<i>TABLE 33 LEADING PHARMA COMPANIES IN RUSSIA, BY MARKET SHARE, 2012 (%)</i>	129
Generics Market	130
CHAPTER 8 THE GLOBAL GENERICS INDUSTRY	132
<i>TABLE 34 LEADING GENERICS COMPANIES, BY SALES, 2015 (\$ BILLIONS)</i>	132
TRENDS	132
STRUCTURE OF THE GENERICS INDUSTRY	133
RECENT M&A ACTIVITY	134
BRAND COMPANY INVOLVEMENT	135
PROFILES OF THE LEADING GENERICS COMPANIES	136
ACTAVIS (TEVA)	136
ASPEN PHARMACARE HOLDINGS LTD.	137
CIPLA LTD.	139
FRESENIUS KABI	140
HOSPIRA INC.	141
Biogenerics	141
Financials	142
LUPIN, LTD.	142
MYLAN INC.	143
SANDOZ INTERNATIONAL GMBH	145
Products	145
SANOFI	147
SUN PHARMACEUTICAL INDUSTRIES LTD.	148
TEVA PHARMACEUTICAL INDUSTRIES LTD.	148
Financials	150
OTHER INTERNATIONAL GENERICS COMPANIES	150
AUROBINDO PHARMA LTD.	150
DR. REDDY'S LABORATORIES LTD.	152
EGIS PHARMACEUTICALS PLC	153

TOPIC	PAGE NO.
APIs	154
KRKA	154
Products	155
PAR PHARMACEUTICAL, INC.	156
Generics	156
STADA ARZNEIMITTEL	157
Generics	157
Biosimilars	158
STRIDES SHASUN LTD.	159
WOCKHARDT LTD.	160
ZYDUS CADILA	161

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR GENERIC DRUGS, BY REGION, THROUGH 2021 (\$ BILLIONS)	9
TABLE 1 GLOBAL PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS)	12
TABLE 2 MAJOR RECENT AND UPCOMING PATENT EXPIRIES, 2014-2020	18
TABLE 3 BRAND SALES BEFORE AND AFTER PATENT EXPIRY (\$ MILLIONS)	19
TABLE 4 BIOTHERAPEUTICS AMONG TOP 40 PRESCRIPTION PHARMACEUTICALS, 2015 (\$ BILLIONS)	24
TABLE 5 BIOLOGICS WITH RECENT OR UPCOMING LOSS OF PATENT PROTECTION	24
TABLE 6 REQUIREMENTS FOR NDA AND ANDA APPLICATIONS	33
TABLE 7 GLOBAL MARKET FOR PHARMA AND GENERIC DRUGS, THROUGH 2021 (\$ BILLIONS)	52
TABLE 8 GLOBAL MARKET FOR GENERIC DRUGS, BY COUNTRY, THROUGH 2021 (\$ BILLIONS)	52
TABLE 9 TOP 20 GENERIC MOLECULES, BY PRESCRIPTION SALES, 2015 (\$ BILLIONS)	53
TABLE 10 GLOBAL TOP-SELLING PRESCRIPTION PHARMACEUTICALS	54
TABLE 11 LEADING ANTI-INFECTIVE PRODUCT SALES, 2015 (\$ MILLIONS)	56
TABLE 12 LEADING CNS PRODUCT SALES, 2015 (\$ MILLIONS)	58
TABLE 13 LEADING CARDIOVASCULAR PRODUCT SALES, 2015 (\$ MILLIONS)	62
TABLE 14 LEADING ANTI-ARTHRITIS PRODUCT SALES, 2015 (\$ MILLIONS)	65
TABLE 15 LEADING RESPIRATORY PRODUCT SALES, 2015 (\$ MILLIONS)	70
TABLE 16 LEADING ANTICANCER PRODUCT SALES, 2015 (\$ MILLIONS)	72
TABLE 17 U.S. PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)	77
TABLE 18 CANADA'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)	80
TABLE 19 BRAZIL'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)	83
TABLE 20 JAPAN'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)	88
TABLE 21 TOP 25 JAPANESE PHARMA COMPANIES (\$ MILLIONS/%)	89
TABLE 22 INDIA'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)	94
TABLE 23 LEADING PHARMA COMPANIES IN INDIA, 2012 (\$ MILLIONS)	96
TABLE 24 CHINA'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)	99
TABLE 25 FRANCE'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)	108
TABLE 26 GERMANY'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)	112
TABLE 27 ITALY'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)	116
TABLE 28 SPAIN'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)	120
TABLE 29 LEADING GENERICS COMPANIES IN SPAIN, 2015 (\$ MILLIONS)	121
TABLE 30 LEADING PHARMA COMPANIES IN THE U.K., BY MARKET SHARE, 2013 (%)	124
TABLE 31 U.K.'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)	125
TABLE 32 RUSSIA'S PHARMACEUTICALS AND GENERICS MARKET, THROUGH 2021 (\$ BILLIONS/%)	129

TABLE HEADING	PAGE NO.
TABLE 33 LEADING PHARMA COMPANIES IN RUSSIA, BY MARKET SHARE, 2012 (%)	129
TABLE 34 LEADING GENERICS COMPANIES, BY SALES, 2015 (\$ BILLIONS)	132

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR GENERIC DRUGS, BY REGION, 2014-2021 (\$ BILLIONS)	9
FIGURE 1 GLOBAL MARKET SHARE OF ASTHMA PRODUCT CATEGORIES (%)	69
FIGURE 2 HEALTH EXPENDITURE IN MAJOR EUROPEAN MARKETS AND THE U.S., 2014 (PERCENTAGE OF GDP)	106